Loading
In jurisdictions that recognize it, the learned intermediary doctrine is a state-law rule that may direct a prescription drug or prescription medical device manufacturer's warning duty to the prescribing physician rather than directly to the patient. Depending on the governing law, the identity of the relevant intermediary may vary.
The doctrine does not automatically defeat a failure-to-warn claim. The dispute may still turn on whether the warning was adequate and whether any deficiency caused the treatment decision or alleged injury.
In Centocor, Inc. v. Hamilton, 372 S.W.3d 140 (Tex. 2012), the Supreme Court of Texas explained that an adequate warning to the prescribing physician can satisfy the manufacturer's duty to warn. If the warning is inadequate, liability still depends on the remaining elements of the claim, including causation.
This guide explains how the doctrine affects warning claims, causation evidence, and the role of qualified expert analysis.
The learned intermediary doctrine does not operate identically in every jurisdiction or apply automatically to every claim involving a prescription product. Counsel should identify the governing state law and determine whether the claim is based on an alleged failure to warn the patient or healthcare professional.
Questions that may affect how the doctrine shapes the claim include:
Whether the jurisdiction recognizes the doctrine for the product and claim at issue.
Whether the warning to the appropriate healthcare professional was adequate under governing law.
Whether the jurisdiction recognizes an exception, such as the direct-to-consumer advertising exception recognized in Perez v. Wyeth Laboratories Inc., 161 N.J. 1, 734 A.2d 1245 (1999).
Whether a separate theory, such as fraud, misrepresentation, design defect, or manufacturing defect, actually depends on the same alleged warning deficiency under governing law.
Whether the person receiving the manufacturer's information qualifies as the relevant intermediary.
These distinctions can shape discovery and expert strategy because separate claims may require different evidence and technical expertise.
The learned intermediary doctrine can shape pharmaceutical and medical device failure-to-warn claims by focusing the warning duty on the prescribing or treating healthcare professional, subject to the governing state law and any recognized exceptions. This article explains how warning adequacy, causation, prescriber testimony, regulatory evidence, and expert analysis may affect these cases, along with the role of Rule 702 in evaluating specialized opinions.
Pharmaceutical Product Liability
Drug Labels
Safety Warnings
FDA Regulation
Causation Analysis
Drug Regulation
Product Safety
Regulatory Issues
In jurisdictions that recognize it, the learned intermediary doctrine is a state-law rule that may direct a prescription drug or prescription medical device manufacturer's warning duty to the prescribing physician rather than directly to the patient. Depending on the governing law, the identity of the relevant intermediary may vary.
The doctrine does not automatically defeat a failure-to-warn claim. The dispute may still turn on whether the warning was adequate and whether any deficiency caused the treatment decision or alleged injury.
In Centocor, Inc. v. Hamilton, 372 S.W.3d 140 (Tex. 2012), the Supreme Court of Texas explained that an adequate warning to the prescribing physician can satisfy the manufacturer's duty to warn. If the warning is inadequate, liability still depends on the remaining elements of the claim, including causation.
This guide explains how the doctrine affects warning claims, causation evidence, and the role of qualified expert analysis.
The learned intermediary doctrine does not operate identically in every jurisdiction or apply automatically to every claim involving a prescription product. Counsel should identify the governing state law and determine whether the claim is based on an alleged failure to warn the patient or healthcare professional.
Questions that may affect how the doctrine shapes the claim include:
Whether the jurisdiction recognizes the doctrine for the product and claim at issue.
Whether the warning to the appropriate healthcare professional was adequate under governing law.
Whether the jurisdiction recognizes an exception, such as the direct-to-consumer advertising exception recognized in Perez v. Wyeth Laboratories Inc., 161 N.J. 1, 734 A.2d 1245 (1999).
Whether a separate theory, such as fraud, misrepresentation, design defect, or manufacturing defect, actually depends on the same alleged warning deficiency under governing law.
Whether the person receiving the manufacturer's information qualifies as the relevant intermediary.
These distinctions can shape discovery and expert strategy because separate claims may require different evidence and technical expertise.
A central question is whether a different warning would have changed the treatment decision or subsequent course of events. Courts do not apply a single nationwide causation test.
In Centocor, the Supreme Court of Texas examined whether the alleged warning deficiency affected the treatment decision. The court held that the plaintiffs could not establish warning causation because there was no evidence that a different warning would have changed the prescribing physicians' decisions, and it also noted that there was no evidence the patient would have acted differently.
California's Supreme Court took up how a plaintiff may prove warning causation in Himes v. Somatics, LLC, 16 Cal. 5th 209 (2024), a medical-device case that reached the court on a question certified by the Ninth Circuit. The court held that, under California's learned intermediary doctrine, warning causation does not require proof that a stronger warning would have led the physician to choose not to prescribe the product. A plaintiff may instead show that the physician would have conveyed the stronger warning to the patient and that an objectively prudent person in the patient's position would have declined treatment despite the physician's continued recommendation.
That distinction can make prescriber testimony, risk disclosures, and patient-specific circumstances important to the causation analysis.
The warning in effect when the treatment decision was made is usually central, along with the labeling history, safety information, and regulatory record.
For prescription drugs, U.S. Food and Drug Administration regulations govern prescribing information, including warnings and precautions, contraindications, and adverse reactions. Under 21 C.F.R. § 801.109, qualifying prescription devices may be exempt from adequate directions for use if specified conditions are met. Those conditions generally include specified labeling information for practitioners, such as relevant hazards, contraindications, side effects, and precautions, subject to the regulation's stated exceptions.
Potentially relevant materials may include:
The label or instructions for use in effect at the time.
Earlier or later warnings when relevant to the warning history.
Clinical studies, published literature, and documented safety information.
FDA regulatory materials.
Manufacturer communications concerning the disputed risk.
For prescription drugs, federal labeling requirements and state-law warning duties may differ. In impossibility-preemption cases, the analysis can turn on the federal requirements applicable to the manufacturer and whether federal law permitted the manufacturer to independently make the change that state law allegedly required.
Warning causation often depends on what information reached the relevant healthcare professional and whether different information would have affected the treatment process under governing law. The factual record may therefore include medical and prescribing records, informed-consent documentation when applicable, and testimony from the prescribing or implanting physician.
That physician may explain what risks the physician knew about, how the treatment decision was made, what information was communicated to the patient, and how additional information would have affected the physician's actions.
Developing this record can also help identify which questions can be addressed by treating or prescribing clinicians and which may require retained expert analysis. A retained expert may address separate matters such as pharmacology, medical causation, regulatory history, device performance, epidemiology, or the scientific evidence associated with the alleged risk.
An expert generally should not offer a legal conclusion about whether the learned intermediary doctrine applies. Expert testimony is better directed to scientific, medical, regulatory, or technical questions underlying warning and causation disputes.
Depending on the issue, qualified professionals may address different parts of the record:
Pharmacology or pharmaceutical experts may analyze drug mechanisms, adverse effects, dose-response relationships, clinical studies, pharmacokinetics, or pharmacodynamics.
Physicians in the relevant specialty may address clinical use, treatment alternatives, recognized risks, differential diagnosis, and medical causation within their qualifications.
Regulatory or drug-labeling specialists may reconstruct labeling history and explain relevant FDA submissions, communications, and regulatory context without offering legal conclusions.
Biomedical engineers or other device specialists may examine design, testing, failure mechanisms, risk controls, instructions for use, and product performance.
The prescribing or implanting physician may also testify about the information reviewed, known risks, treatment rationale, and how additional information would have affected that physician's decision. Depending on the scope of the testimony and the governing procedural rules, expert-disclosure and admissibility requirements may apply.
In federal court, Rule 702 requires the proponent to show the court that it is more likely than not that four requirements are met. The expert's specialized knowledge must help the trier of fact understand the evidence or determine a fact in issue. The testimony must be based on sufficient facts or data and be the product of reliable principles and methods. The expert's opinion must also reflect a reliable application of those principles and methods to the facts of the case.
The expert's qualifications and methodology should fit the issue being addressed. Expertise in pharmacology, for example, does not automatically qualify a witness to address medical-device engineering, and regulatory experience alone does not establish expertise in patient-specific medical causation.
Counsel should keep three questions distinct:
What did the manufacturer communicate about the risk?
Would different information have affected the treatment process under governing law?
Did the product cause the alleged injury?
Keeping these questions separate helps align each opinion with the expert's qualifications and the requirements of Rule 702.
What is the learned intermediary doctrine?
In jurisdictions that recognize it, the learned intermediary doctrine may allow a manufacturer of a prescription drug or prescription medical device to satisfy its warning duty by adequately warning the appropriate healthcare professional rather than the patient directly. The precise rule varies by jurisdiction.
Does the learned intermediary doctrine automatically defeat a failure-to-warn claim?
No. A dispute may remain over whether the warning to the healthcare professional was adequate and whether any alleged deficiency caused the treatment decision or injury under the controlling state's law.
Does the doctrine apply to prescription medical devices?
It can. Courts, including the Supreme Court of California in Himes v. Somatics, LLC, have applied the doctrine to prescription medical devices, although the governing state's law controls.
Does direct-to-consumer advertising create an exception?
The answer depends on the jurisdiction. The Supreme Court of New Jersey recognized a direct-to-consumer advertising exception in Perez v. Wyeth Laboratories Inc. In Centocor, Inc. v. Hamilton, the Supreme Court of Texas held that no such exception applied on the facts before it and left open whether Texas law might recognize one if a manufacturer directly provides patients or prospective patients with information that is intentionally misleading.
What experts may be relevant to a learned intermediary dispute?
The appropriate discipline depends on the disputed issue. Relevant expertise may include pharmacology, clinical medicine, regulatory affairs, epidemiology, or biomedical engineering.
A central question is whether a different warning would have changed the treatment decision or subsequent course of events. Courts do not apply a single nationwide causation test.
In Centocor, the Supreme Court of Texas examined whether the alleged warning deficiency affected the treatment decision. The court held that the plaintiffs could not establish warning causation because there was no evidence that a different warning would have changed the prescribing physicians' decisions, and it also noted that there was no evidence the patient would have acted differently.
California's Supreme Court took up how a plaintiff may prove warning causation in Himes v. Somatics, LLC, 16 Cal. 5th 209 (2024), a medical-device case that reached the court on a question certified by the Ninth Circuit. The court held that, under California's learned intermediary doctrine, warning causation does not require proof that a stronger warning would have led the physician to choose not to prescribe the product. A plaintiff may instead show that the physician would have conveyed the stronger warning to the patient and that an objectively prudent person in the patient's position would have declined treatment despite the physician's continued recommendation.
That distinction can make prescriber testimony, risk disclosures, and patient-specific circumstances important to the causation analysis.
The warning in effect when the treatment decision was made is usually central, along with the labeling history, safety information, and regulatory record.
For prescription drugs, U.S. Food and Drug Administration regulations govern prescribing information, including warnings and precautions, contraindications, and adverse reactions. Under 21 C.F.R. § 801.109, qualifying prescription devices may be exempt from adequate directions for use if specified conditions are met. Those conditions generally include specified labeling information for practitioners, such as relevant hazards, contraindications, side effects, and precautions, subject to the regulation's stated exceptions.
Potentially relevant materials may include:
The label or instructions for use in effect at the time.
Earlier or later warnings when relevant to the warning history.
Clinical studies, published literature, and documented safety information.
FDA regulatory materials.
Manufacturer communications concerning the disputed risk.
For prescription drugs, federal labeling requirements and state-law warning duties may differ. In impossibility-preemption cases, the analysis can turn on the federal requirements applicable to the manufacturer and whether federal law permitted the manufacturer to independently make the change that state law allegedly required.
Warning causation often depends on what information reached the relevant healthcare professional and whether different information would have affected the treatment process under governing law. The factual record may therefore include medical and prescribing records, informed-consent documentation when applicable, and testimony from the prescribing or implanting physician.
That physician may explain what risks the physician knew about, how the treatment decision was made, what information was communicated to the patient, and how additional information would have affected the physician's actions.
Developing this record can also help identify which questions can be addressed by treating or prescribing clinicians and which may require retained expert analysis. A retained expert may address separate matters such as pharmacology, medical causation, regulatory history, device performance, epidemiology, or the scientific evidence associated with the alleged risk.
An expert generally should not offer a legal conclusion about whether the learned intermediary doctrine applies. Expert testimony is better directed to scientific, medical, regulatory, or technical questions underlying warning and causation disputes.
Depending on the issue, qualified professionals may address different parts of the record:
Pharmacology or pharmaceutical experts may analyze drug mechanisms, adverse effects, dose-response relationships, clinical studies, pharmacokinetics, or pharmacodynamics.
Physicians in the relevant specialty may address clinical use, treatment alternatives, recognized risks, differential diagnosis, and medical causation within their qualifications.
Regulatory or drug-labeling specialists may reconstruct labeling history and explain relevant FDA submissions, communications, and regulatory context without offering legal conclusions.
Biomedical engineers or other device specialists may examine design, testing, failure mechanisms, risk controls, instructions for use, and product performance.
The prescribing or implanting physician may also testify about the information reviewed, known risks, treatment rationale, and how additional information would have affected that physician's decision. Depending on the scope of the testimony and the governing procedural rules, expert-disclosure and admissibility requirements may apply.
In federal court, Rule 702 requires the proponent to show the court that it is more likely than not that four requirements are met. The expert's specialized knowledge must help the trier of fact understand the evidence or determine a fact in issue. The testimony must be based on sufficient facts or data and be the product of reliable principles and methods. The expert's opinion must also reflect a reliable application of those principles and methods to the facts of the case.
The expert's qualifications and methodology should fit the issue being addressed. Expertise in pharmacology, for example, does not automatically qualify a witness to address medical-device engineering, and regulatory experience alone does not establish expertise in patient-specific medical causation.
Counsel should keep three questions distinct:
What did the manufacturer communicate about the risk?
Would different information have affected the treatment process under governing law?
Did the product cause the alleged injury?
Keeping these questions separate helps align each opinion with the expert's qualifications and the requirements of Rule 702.
What is the learned intermediary doctrine?
In jurisdictions that recognize it, the learned intermediary doctrine may allow a manufacturer of a prescription drug or prescription medical device to satisfy its warning duty by adequately warning the appropriate healthcare professional rather than the patient directly. The precise rule varies by jurisdiction.
Does the learned intermediary doctrine automatically defeat a failure-to-warn claim?
No. A dispute may remain over whether the warning to the healthcare professional was adequate and whether any alleged deficiency caused the treatment decision or injury under the controlling state's law.
Does the doctrine apply to prescription medical devices?
It can. Courts, including the Supreme Court of California in Himes v. Somatics, LLC, have applied the doctrine to prescription medical devices, although the governing state's law controls.
Does direct-to-consumer advertising create an exception?
The answer depends on the jurisdiction. The Supreme Court of New Jersey recognized a direct-to-consumer advertising exception in Perez v. Wyeth Laboratories Inc. In Centocor, Inc. v. Hamilton, the Supreme Court of Texas held that no such exception applied on the facts before it and left open whether Texas law might recognize one if a manufacturer directly provides patients or prospective patients with information that is intentionally misleading.
What experts may be relevant to a learned intermediary dispute?
The appropriate discipline depends on the disputed issue. Relevant expertise may include pharmacology, clinical medicine, regulatory affairs, epidemiology, or biomedical engineering.
Pharmaceutical Product Liability
Drug Labels
Safety Warnings
FDA Regulation
Causation Analysis
Drug Regulation
Product Safety
Regulatory Issues
Legal Standards
Legal Standards
